Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CEST

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
06:39p FITCH : Ohio Supreme Court Order Could Pressure DPL and DP&L's Ratings
06:38p SAIPEM : Board of Directors approves launch of non-convertible bond issuance programme for a maximum amount of €1.6 billion
06:38p CALIFORNIA POULTRY FEDERATION : New CDC report links salmonella outbreaks with backyard flocks
06:38p PHOTO ME : Block listing Interim Review
06:38p CALIFORNIA POULTRY FEDERATION : Organic industry fights for better animal welfare
06:38p COMMENTARY : International trade pacts mean more U.S. ag dollars
06:38p SURGICAL INNOVATIONS : Issue of Shares
06:38p DO DEUTSCHE OFFICE : Deutsche Office leases 2,500 sqm in Cologne
06:38p SURGICAL INNOVATIONS : Result of Annual General Meeting
06:38p UNIVERSITY OF MANCHESTER : 27 Jun 2016 - Global poverty expert says urgent action needed to help the world’s poorest
Latest news
Advertisement
Hot News 
SWEETT : The K2 Principal Fund L.P. - Public Opening Position Disclosure
HEARTWARE : Medtronic to Expand Heart Failure Portfolio with Acquisition of Heartware International
PEOPLE'S UNITED FINANCIAL, INC. : To Acquire Suffolk Bancorp
MORTGAGE ADVICE BUREAU : Expects Fewer Transactions After Brexit Vote
INTERQUEST : Trading Update
Most Read News
10:42a Oil down 2 percent as dollar strength, Brexit uncertainty continue
02:49aDJFRESENIUS SE KGAA : CEO Is Leaving His Post -- WSJ
Most recommended articles
12:37p UBS : French prosecutor seeks trial for UBS over client tax fraud-judicial source
12:35pDJNestlé Taps Ulf Mark Schneider as Next CEO
12:35pDJBrexit' Bookings Strong But Fares Lower, Says Ryanair
12:34p SUNOPTA : hires advisers after shareholder urges sale of company
12:33p Brexit vote wipes $130 billion off FTSE 100 in two days; banks slump